A study has described the long-term adherence, efficacy, and safety in patients with psoriatic arthritis ( PsA ) treated with Etanercept ( Enbrel ) in a daily clinical setting in Belgium.
The PROVE study was a prospective, multi-centre, open-label, observational study in patients with active psoriatic arthritis who had previously failed disease-modifying anti-rheumatic drugs.
Patients were treated with Etanercept prescribed by their physician and adherence was monitored over 66 months.
A total of 303 patients were enrolled ( polyarticular-type n=264; oligoarticular-type n=39 ). 156 ( 51.5% ) patients adhered to the treatment until the end of the study.
The mean study duration was 4.0 ( SD, 1.9 ) years.
The most common reasons for discontinuing were non-response ( 35.9% ), patient lost to follow-up ( 20.7% ), and reasons unrelated to Etanercept ( 20.0% ).
Males adhered to treatment significantly longer than females ( 5.0 vs. 3.9 years; p less than 0.0001 ).
After 6 months, 49.0% of patients with active synovitis at the start of the study had zero joints with synovitis, and this proportion increased to 77.6% by month 66 ( p less than 0.001 for all time points vs baseline ).
In polyarticular-type patients, the mean total Health Assessment Questionnaire ( HAQ ) score ( 0-60 ) decreased from 27.0 ( 95% CI 25.9-28.1 ) to 9.7 ( 8.5-10.9; 64.8% improvement; p less than 0.001 ) after 6 months and to 7.7 ( 6.2-9.3; 66.6% improvement; p less than 0.001 ) after 66 months.
Treatment-related adverse events were reported in 177 ( 58.8% ) of patients, and 53 ( 17.6% ) patients reported serious adverse events related to treatment.
In conclusion, in these patients with active psoriatic arthritis from daily clinical practice, adherence to Etanercept was high observed over 5.5 years and it was well tolerated. ( Xagena )
de Vlam K et al, Clin Exp Rheumatol 2015;33:624-631